Clinical Effect of Kaixin Xiaoyao Decoction and Sacubitril Alsartan in the Treatment of Chronic Heart Failure Complicated with Hypertension
Objective To explore the clinical efficacy of Kaixin Xiaoyao Decoction and sacubitril alsartan in the treatment of patients with CHF and hypertension.Methods A total of 75 patients with CHF complicated with hypertension who were admitted in Zhumadian Traditional Chinese Medicine Hospital from March 2022 to February 2023 were selected,and randomly divided into the study group(37 cases)and the control group(38 cases).The control group was treated with sacubitril alsartan,while the study group was treated with Kaixin Xiaoyao Decoction and sacubitril alsartan.The clinical efficacy,blood pressure levels,heart function,and myocardial injury indicators in both groups were compared.Results In comparison of the control group(65.79％),the total effective rate of the study group(86.49％)was higher(P＜0.05).After treatment.the systolic blood pressure(SBP),diastolic blood pressure(DBP)levels in both groups were decreased(P＜0.05),and in comparison of the control group,the study group was lower(P＜0.05).After treatment,the left ventricular ejection fraction(LVEF),cardiac output(SV)in both groups were increased(P＜0.05),left ventricular mass index(LVMI)were decreased(P＜0.05),in comparison of the control group,the LVEF and SV of the study group was higher(P＜0.05),the LVMI was lower(P＜0.05).After treatment,the N-terminal B-type natriuretic peptide precursor(NT-proBNP),cardiac troponin(cTn)Ⅰ,matrix metalloproteinase 9(MMP-9)in both groups were decreased(P＜0.05),and in comparison of the control group,the study group was lower(P＜0.05).Conclusion The treatment of patients with CHF and hypertension with Kaixin Xiaoyao Decoction and sacubitril alsartan can improve clinical efficacy,stabilize blood pressure levels,and improve patient cardiac function and myocardial injury indicators.
万方数据
维普
